New antibiotic shows promise for fast UTI symptom relief in women

NCT ID NCT06597344

Completed Symptom relief Sponsor: GlaxoSmithKline Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed Phase 3 trial tested the antibiotic gepotidacin in 97 adolescent and adult women with uncomplicated urinary tract infections (UTIs). The goal was to see if symptoms like pain and urgency improved within 24 hours. Researchers measured symptom scores and safety. The study was open-label, meaning everyone knew they were getting the drug, and there was no placebo group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: gepotidacin
What this could lead to: If successful, this could provide a new oral antibiotic option for quickly easing UTI symptoms in women and teens.
What could go wrong: This is a single-arm, open-label study with no placebo comparison, so results may be less reliable. The trial is also small (97 participants) and completed, so further studies may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UNCOMPLICATED URINARY TRACT INFECTION (ACUTE CYSTITIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute cystitis urinary tract infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

URINARY TRACT INFECTIONS

Contacts and locations

Locations

GSK Investigational Site

Modesto, California, 95350-5365, United States
GSK Investigational Site

Pasadena, California, 91101-2453, United States
GSK Investigational Site

San Diego, California, 92120-5259, United States
GSK Investigational Site

Valencia, California, 91355, United States
GSK Investigational Site

Miami, Florida, 33135, United States
GSK Investigational Site

Ormond Beach, Florida, 32174-6302, United States
GSK Investigational Site

Palm Springs, Florida, 33406-7671, United States
GSK Investigational Site

Palm Springs, Florida, 33461, United States
GSK Investigational Site

Plant City, Florida, 33563-4202, United States
GSK Investigational Site

Sweetwater, Florida, 33172-2741, United States
GSK Investigational Site

West Palm Beach, Florida, 33409-3401, United States
GSK Investigational Site

West New York, New Jersey, 07093-2622, United States
GSK Investigational Site

New York, New York, 10016-7313, United States
GSK Investigational Site

Dayton, Ohio, 45424, United States
GSK Investigational Site

Forney, Texas, 75126-4174, United States
GSK Investigational Site

Houston, Texas, 77036, United States
GSK Investigational Site

Houston, Texas, 77087, United States
GSK Investigational Site

Kingwood, Texas, 26537, United States
GSK Investigational Site

Mesquite, Texas, 75149, United States
GSK Investigational Site

Missouri City, Texas, 77459-4756, United States
GSK Investigational Site

Bountiful, Utah, 84010-4943, United States
GSK Investigational Site

Morgantown, West Virginia, 26501, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.